
Not Just Ventilators: Staff Trained to Run Them Are in Short Supply
Each patient on a breathing machine requires multiple doctors and nurses to care for that person

Karen Weintraub is a staff writer at USA Today, where she covers COVID, vaccine development and other health issues. Credit: Nick Higgins

Each patient on a breathing machine requires multiple doctors and nurses to care for that person

A team at Boston Children’s Hospital is searching for ways to boost a vaccine’s effectiveness for those who need it most

Voters exposed to such untrustworthy sources also see valid news online, a study finds

The protein, once seen as a secondary player, has taken a leading role in combating neurodegenerative illnesses

Columbia University professor W. Ian Lipkin looks for lessons from the new disease COVID-19 to prevent the next disaster

EEGs successfully picked out which depressed individuals got better on the drug Zoloft

Snags hinder efforts to create small cellular models of the human cortex

Eight years of experiments demonstrate the bridging of large gaps in damaged nerves

A new study finds that they have dropped, on average, over the past century and a half

It may open the door to new treatments and explain why previous ones failed

Even combination therapies do not prevent such pathogens from becoming resistant

The technology embeds immunization records into a child’s skin

Will the benefits of aducanumab be enough to justify FDA approval, given its small benefit and high price?

Although not practical in many areas, the approach reveals clues to how the immune system battles the infection

The surveillance of viral changes persists to keep the blood supply safe

The finding that the virus causes “immune amnesia” further highlights the importance of vaccination

U.C.S.F. researchers find a gene for flourishing with less shut-eye

Approaches for boosting the body’s immune system are being tried for autoimmune and heart conditions, but it is too early to know how well they will work in people

The technology that produced a global scandal in China last year has entered into clinical trials to treat sickle cell anemia and an eye disease

The bacteria are not a major threat, but they could transfer their resistance to more dangerous pathogens
Support science journalism.

Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account